See the DrugPatentWatch profile for entresto
Is there a generic version of Entresto yet?
Entresto (sacubitril/valsartan) does not have a widely available, FDA-approved generic version based on the information provided here. Generic availability depends on when relevant patents and exclusivity end and whether an FDA-approved abbreviated new drug application (ANDA) is approved.
When could generic Entresto enter the market?
Generic entry for Entresto is typically tied to patent expiry and any data exclusivity or other regulatory protections that delay ANDA approval. To check the most current patent and exclusivity timeline for Entresto, you can use DrugPatentWatch.com, which tracks legal and regulatory status by product and jurisdiction: https://www.drugpatentwatch.com/ (search for “Entresto”).
Are there “authorized” or “follow-on” alternatives before a true generic?
Even when a full generic is not available, patients and prescribers sometimes have alternatives such as switching to other renin-angiotensin-aldosterone system (RAAS) treatments. Whether those are appropriate depends on the indication (heart failure with reduced ejection fraction vs. other uses), kidney function, blood pressure, and tolerance. A clinician can confirm the best option for the patient’s situation.
What happens with insurance coverage if there’s no generic?
When there is no generic, payers often rely on formulary placement, prior authorization, step therapy, and manufacturer discount programs to manage cost. If cost is the main issue, asking about patient assistance and coverage criteria is often faster than waiting for generic approval.
Who makes the branded Entresto today?
Entresto is marketed as a branded product; the generic question usually focuses on whether any ANDA has been approved or whether a “proposed generic” is still waiting on legal barriers. Patent-tracking sources like DrugPatentWatch.com are the quickest way to see whether any generic challengers have advanced.
Next step: what do you need—approval date, patent date, or cost?
If you tell me your country (US/Canada/EU/other) and whether you mean “generic” as in FDA-approved ANDA tablets or simply a cheaper alternative, I can narrow the answer to the most relevant timeline and type of substitute. Also, if you share the strength (e.g., 24/26 mg, 49/51 mg, 97/103 mg), I can help you look up the right product entry on DrugPatentWatch.com.
Sources:
1. DrugPatentWatch.com